FTase antagonist | FTase inhibitor | FTase agonist

Catalog No.	Product Name	Information	Product Use Citations
S1453	Tipifarnib	Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. Phase 3.	Sci Rep, 2025, 15(1):6832 Cell Rep, 2023, 42(9):113098 iScience, 2023, 26(5):106695
S7465	FTI 277 HCl	FTI 277 HCl is a potent and selective farnesyltransferase (FTase) inhibitor with IC50 of 500 pM, about 100-fold selectivity over the closely related GGTase I. FTI 277 HCl inhibits cell growth and induces apoptosis. FTI 277 HCl is effective in clearing HDV viremia.	EMBO J, 2025, 44(4):1185-1219 Cancer Res, 2023, 83(13):2248-2261 PLoS Biol, 2021, 19(4):e3001134
S7467	LB42708	LB42708 is an orally active farnesyltransferase (FTase) inhibitor with IC50 of 0.8, 1.2, and 2.0 nM toward H-ras, N-ras, and K-ras, respectively.	Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
S1453	Tipifarnib	Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. Phase 3.	Sci Rep, 2025, 15(1):6832 Cell Rep, 2023, 42(9):113098 iScience, 2023, 26(5):106695
S7465	FTI 277 HCl	FTI 277 HCl is a potent and selective farnesyltransferase (FTase) inhibitor with IC50 of 500 pM, about 100-fold selectivity over the closely related GGTase I. FTI 277 HCl inhibits cell growth and induces apoptosis. FTI 277 HCl is effective in clearing HDV viremia.	EMBO J, 2025, 44(4):1185-1219 Cancer Res, 2023, 83(13):2248-2261 PLoS Biol, 2021, 19(4):e3001134
S7467	LB42708	LB42708 is an orally active farnesyltransferase (FTase) inhibitor with IC50 of 0.8, 1.2, and 2.0 nM toward H-ras, N-ras, and K-ras, respectively.	Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221

FTase

FTase Products

Choose Selective FTase Inhibitors